COVID-19 Update: All AMP Locations are open, see how we are offering safe in person care and virtual visits. Click here to Learn more about Virtual Care Options.

Click here for additional COVID-19 Information

Non-Discrimination Notice

CUSP Merck 057

Merck 057- A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475)

Population:

High risk NMIBC Unresponsive to BCG Therapy.

*Only CIS arm open.

Sponsored by: CUSP
Enrollment: Open

Please contact one of our Clinical Research Coordinators today to find out more information if you are interested in this trial.

Research Department (315) 478-4185, option 3